CN Patent

CN118852044A — 一种肽脲素衍生物、含其的药物组合物及其应用

Assigned to Jinghe Biomedical Technology Nanjing Co ltd · Expires 2024-10-29 · 2y expired

What this patent protects

本发明公开了一种肽脲素衍生物、含其的药物组合物及其应用。该衍生物如式I所示。该衍生物既可以用于PSMA阳性前列腺癌的手术前显影诊断及分级，也可以用于各个分型和分期的前列腺癌的治疗，达到诊疗一体化，具有广泛的应用前景。

USPTO Abstract

本发明公开了一种肽脲素衍生物、含其的药物组合物及其应用。该衍生物如式I所示。该衍生物既可以用于PSMA阳性前列腺癌的手术前显影诊断及分级，也可以用于各个分型和分期的前列腺癌的治疗，达到诊疗一体化，具有广泛的应用前景。

Drugs covered by this patent

Patent Metadata

Patent number
CN118852044A
Jurisdiction
CN
Classification
—
Expires
2024-10-29
Drug substance claim
No
Drug product claim
No
Assignee
Jinghe Biomedical Technology Nanjing Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.